Similar articles

• [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].

  Giachino G, Giacchino F, Jeantet A, Del Piano A, Garetto A, Pellerey M, Piccoli G. Giachino G, et al. Minerva Med. 1985 Mar 10;76(9-10):407-14. Minerva Med. 1985. PMID: 2984605 Italian. No abstract available.
• Disordered divalent ion metabolism in kidney disease: comments on pathogenesis and treatment.

  Brautbar N, Kleeman CR. Brautbar N, et al. Adv Nephrol Necker Hosp. 1979;8:179-205. Adv Nephrol Necker Hosp. 1979. PMID: 227253 Review. No abstract available.
• [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy].

  Di Landro D, Zanatta GP, Simioni N, Pinzani A, Zotti D, Perin N, Bertoli M, Naso A, Ruffatti A, Gasparotto ML, et al. Di Landro D, et al. Minerva Med. 1985 Mar 10;76(9-10):419-23. Minerva Med. 1985. PMID: 3982699 Italian. No abstract available.
• [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].

  Bucciante G, Bernardi A, Biasia F, Milan G, Donato D. Bucciante G, et al. Minerva Med. 1985 Mar 10;76(9-10):415-7. Minerva Med. 1985. PMID: 3982698 Italian. No abstract available.
• [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].

  Goto S, Fukagawa M. Goto S, et al. Clin Calcium. 2007 Dec;17(12):1830-4. Clin Calcium. 2007. PMID: 18057657 Review. Japanese.